The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

April 11, 2022

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.

April 10, 2022

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.

April 10, 2022

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

April 07, 2022

Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with breast cancer, and potential avenues for future investigations.

April 01, 2022

Srdan Verstovsek, MD, PhD, discusses the efficacy of momelotinib in myelofibrosis.

March 24, 2022

Tapan M. Kadia, MD, discusses the utilization of uproleselan with chemotherapy in relapsed/refractory acute myeloid leukemia.

March 24, 2022

James P. Allison, PhD, a Nobel Laureate and Giants of Cancer Care® award winner, will head up the new James P. Allison Institute at The University of Texas MD Anderson Cancer Center.

March 24, 2022

Debu Tripathy, MD, discusses the implications of results from the phase 3 NALA trial in patients with HER2-positive metastatic breast cancer with brain metastases.

March 18, 2022

Hussein A. Tawbi, MD, PhD, discusses the FDA approval of relatlimab plus nivolumab in unresectable or metastatic melanoma.

March 05, 2022

Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.

March 04, 2022

Debu Tripathy, MD, discusses the emergence of genomics research in breast cancer.

March 02, 2022

Jason R. Westin, MD, director, discusses the utilization of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

March 01, 2022

The MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared with current standard-of-care therapies in patients with relapsed or persistent low-grade serous ovarian carcinoma, making it the potential new SOC for this patient population.

March 01, 2022

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

March 01, 2022

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

March 01, 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the utilization of circulating tumor DNA in colorectal cancer.

March 01, 2022

Michael Wang, MD, discusses adverse effects associated with BTK inhibitors in patients with mantle cell lymphoma.

February 25, 2022

Kanwal P.S. Raghav, MBBS, MD, discusses on the utilization of circulating tumor DNA in metastatic colorectal cancer.

February 24, 2022

Michael Wang, MD, discusses potential adverse effects associated with ibrutinib in patients with mantle cell lymphoma.

February 23, 2022

Michael Wang, MD, discusses the sequencing of oral therapies in mantle cell lymphoma.